Last updated on June 2019

Study in Subjects With Moderate Atopic Dermatitis


Brief description of study

This is a Phase 2, randomized, double-blind, vehicle-controlled, parallel-group study to evaluate the safety and efficacy of ALX-101 Gel 5% and a matching ALX-101 Gel Vehicle when applied topically twice daily for 56 days in adult and adolescent subjects with moderate atopic dermatitis

Detailed Study Description

The main objectives of this study are to:

  • Evaluate the safety of ALX-101 Gel 5% when applied topically twice daily in subjects with moderate atopic dermatitis compared with a matching ALX-101 Gel Vehicle
  • Evaluate the efficacy of ALX-101 Gel 5% when applied topically twice daily in subjects with moderate atopic dermatitis compared with a matching ALX-101 Gel Vehicle

Clinical Study Identifier: NCT03859986

Find a site near you

Start Over

Ralexar Investigational Site 10

Beverly Hills, CA United States
  Connect »

Ralexar Investigational Site 5

Los Angeles, CA United States
  Connect »

Ralexar Investigational Site 2

Jacksonville, FL United States
  Connect »

Ralexar Investigational Site 18

Pinellas Park, FL United States
  Connect »

Ralexar Investigational Site 1

Indianapolis, IN United States
  Connect »

Ralexar Investigational Site 17

Louisville, KY United States
  Connect »

Ralexar Investigational Site 9

Oklahoma City, OK United States
  Connect »

Ralexar Investigational Site 19

Spartanburg, SC United States
  Connect »

Ralexar Investigational Site 4

San Antonio, TX United States
  Connect »